CL2020000175A1 - Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina. - Google Patents

Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina.

Info

Publication number
CL2020000175A1
CL2020000175A1 CL2020000175A CL2020000175A CL2020000175A1 CL 2020000175 A1 CL2020000175 A1 CL 2020000175A1 CL 2020000175 A CL2020000175 A CL 2020000175A CL 2020000175 A CL2020000175 A CL 2020000175A CL 2020000175 A1 CL2020000175 A1 CL 2020000175A1
Authority
CL
Chile
Prior art keywords
bst1
antibodies against
pharmaceutical combinations
citadine
ribosil
Prior art date
Application number
CL2020000175A
Other languages
English (en)
Inventor
Cecilia Simonelli
Andrea Pellacani
Monica Binaschi
Corrado Carrisi
Daniela Bellarosa
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of CL2020000175A1 publication Critical patent/CL2020000175A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN ANTICUERPOS CONTRA BST1 (ADP–RIBOSIL CICLASA 2) JUNTO CON UN ANÁLOGO DE CITIDINA O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, Y MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO CÁNCERES MEDIADOS POR LA EXPRESIÓN / ACTIVIDAD DE BST1 (ADP–RIBOSIL CICLASA 2) Y/O ASOCIADOS CON LA EXPRESIÓN / ACTIVIDAD ANORMAL DE BST1.
CL2020000175A 2017-07-21 2020-01-20 Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina. CL2020000175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies

Publications (1)

Publication Number Publication Date
CL2020000175A1 true CL2020000175A1 (es) 2020-06-12

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000175A CL2020000175A1 (es) 2017-07-21 2020-01-20 Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina.

Country Status (22)

Country Link
US (1) US20200231694A1 (es)
EP (1) EP3655033A1 (es)
JP (1) JP2020527594A (es)
KR (1) KR20200032162A (es)
CN (1) CN111132697A (es)
AR (1) AR112460A1 (es)
AU (1) AU2018303241A1 (es)
BR (1) BR112020001320A2 (es)
CA (1) CA3070264A1 (es)
CL (1) CL2020000175A1 (es)
CO (1) CO2020001792A2 (es)
EA (1) EA202090333A1 (es)
GB (1) GB201711785D0 (es)
IL (1) IL272096A (es)
MA (1) MA49627A (es)
MX (1) MX2020000752A (es)
PH (1) PH12020550024A1 (es)
SG (1) SG11202000390TA (es)
TW (1) TW201907952A (es)
UY (1) UY37815A (es)
WO (1) WO2019016371A1 (es)
ZA (1) ZA202000881B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
KR102058185B1 (ko) * 2011-06-28 2019-12-20 옥스포드 바이오테라퓨틱스 리미티드 Adp-리보실 시클라제 2에 대한 항체
GB201806084D0 (en) * 2018-04-13 2018-05-30 Berlin Chemie Ag Antibodies
CN118178645A (zh) * 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Also Published As

Publication number Publication date
MA49627A (fr) 2020-05-27
CA3070264A1 (en) 2019-01-24
MX2020000752A (es) 2020-08-17
EP3655033A1 (en) 2020-05-27
GB201711785D0 (en) 2017-09-06
JP2020527594A (ja) 2020-09-10
AU2018303241A1 (en) 2020-02-20
UY37815A (es) 2019-02-28
SG11202000390TA (en) 2020-02-27
IL272096A (en) 2020-03-31
TW201907952A (zh) 2019-03-01
KR20200032162A (ko) 2020-03-25
AR112460A1 (es) 2019-10-30
US20200231694A1 (en) 2020-07-23
CN111132697A (zh) 2020-05-08
ZA202000881B (en) 2021-08-25
CO2020001792A2 (es) 2020-07-31
EA202090333A1 (ru) 2020-05-06
WO2019016371A1 (en) 2019-01-24
PH12020550024A1 (en) 2021-02-15
BR112020001320A2 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2018002359A1 (es) Métodos para usar agonistas de fxr
CL2017002904A1 (es) Métodos y kits para tratar la depresión
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
SV2018005633A (es) Derivados de heteroarilo como inhibidores de parp
CL2019002869A1 (es) Inhibidores selectivos hdac6.
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
BR112018016729A2 (pt) novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
NI202100018A (es) Moduladores de la expresión de pnpla3
ECSP19077969A (es) Compuesto heterociclico
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
PE20161509A1 (es) Sistemas, metodos y kits de limpieza de una region ocular
DOP2021000130A (es) Moduladores de la expresion de hsd17b13
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CR20190471A (es) Moduladores de la expresión de pcsk9
CO2021007006A2 (es) Moduladores de la expresión de irf5
CL2020000176A1 (es) Pautas para el tratamiento de infecciones por el vih y sida.
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
CL2020000175A1 (es) Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina.
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CL2020000586A1 (es) Moduladores de la expresión de enac.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.